Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer
Prostate Neoplasm
Explore 70 assets in Prostate Neoplasm →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Pfizer
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
36High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00976508CT.gov Figitumumab Combined With Pegvisomant For Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00313781CT.gov Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer (this asset) | Pfizer | P2 | CCC · 50 |
| Docetaxel | Merck Sharp & Dohme LLC | P4 | BBB |
| Prednisone | Merck Sharp & Dohme LLC | P3 | BBB |
| Degarelix | Novartis Pharmaceuticals | P4 | BBB |
| Abiraterone | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Leuporelin | Dana-Farber Cancer Institute | P4 | BB |
| Radium Ra-223 | Bayer | P3 | BB |
| Prednisolone | Eli Lilly and Company | P3 | BB |
| Gozetotide | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
+42 more in the Prostate Neoplasm cohort
Other indications for Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P2 | CCC · 51 |
| Non-Small Cell Lung Carcinoma | — | P3 | CCC · 50 |
| Lung Large Cell Carcinoma | — | P3 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer in Prostate Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g2-anti-human-insulin-like-growth-factor-i-receptor-human-monoclonal-cp-751871-clone-2132-heavy-chain-disulphide-with-human-monoclonal-cp-751871-clone-2132-light-chain-dimer-prostate-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →